3-Sulfanyl-2-[2-[(2-sulfanylacetyl)amino]ethylamino]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Sulfanyl-2-[2-[(2-sulfanylacetyl)amino]ethylamino]propanoic acid
• 化学式: C₇H₁₄N₂O₃S₂
• 分子量: 238.3
• InChiKey: ROBZOQQYRLBBPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  80.4
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：US10874753B2

  公开（公告）日：2020-12-29

  This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.

  本发明涉及用于改进癌症诊断和治疗方法的新型放射性药物共轭物。放射性药物共轭物依次包括：一种靶向肿瘤细胞的代谢物，与一种能够包含放射性核素的螯合剂结合，与一种能够在体外或体内与 EPR 制剂结合的连接体结合；或一种能够包含放射性核素的螯合剂，与一种靶向肿瘤细胞的代谢物结合，与一种能够在体外或体内与 EPR 制剂结合的连接体结合。本发明的放射性药物共轭物提供了主动和被动的靶向放射性核素递送系统，有助于改善用于诊断和治疗癌症的放射性药物的生物分布和药理毒性。
• RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：EP3197504A2

  公开（公告）日：2017-08-02
• RADIOPHARMACEUTICAL CONJUGATE
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：US20170296684A1

  公开（公告）日：2017-10-19

  This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.
• [EN] RADIOPHARMACEUTICAL CONJUGATE<br/>[FR] CONJUGUÉS RADIOPHARMACEUTIQUES
  申请人：SOUTH AFRICAN NUCLEAR ENERGY

  公开号：WO2016046793A2

  公开（公告）日：2016-03-31

  This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide.bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radionuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.
• [EN] IMAGING AGENT<br/>[FR] AGENT D'IMAGERIE
  申请人：THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LTD

  公开号：WO2018178923A1

  公开（公告）日：2018-10-04

  This invention relates to a bioconjugate comprising a chelating agent capable of containing a radionuclide linked to Substance P for use as an imaging agent in a method for detection of increased availability of NK-1 receptors for diagnosing pain, especially chronic pain. The invention also relates to the treatment of pain.